When does MPEP 2412.03(e) apply to patent applications?

The applicability of MPEP 2412.03(e) is clearly stated in the section: “[Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).]” This means that the definition and requirements for “Modified Nucleotide” apply to patent applications…

Read More

How does MPEP 2401 relate to the broader context of biotechnology patents?

MPEP 2401 serves as an introduction to the broader context of biotechnology patents by highlighting two critical aspects: Biological material deposits Sequence disclosures As stated in MPEP 2401: “This chapter provides guidance on the practices and procedures pertaining to the rules for deposits of biological materials for patent purposes ( 37 CFR 1.801 – 1.809…

Read More

What is the purpose of MPEP 2401?

MPEP 2401 serves as an introduction to the chapter on biotechnology in the Manual of Patent Examining Procedure. Specifically, it states: “This chapter provides guidance on the practices and procedures pertaining to the rules for deposits of biological materials for patent purposes ( 37 CFR 1.801 – 1.809 ) and the rules for the requirements…

Read More

How does the definition of “Modified Nucleotide” in MPEP 2412.03(e) affect patent applications?

The definition of “Modified Nucleotide” in MPEP 2412.03(e) affects patent applications in several ways: Application Date: It applies to applications filed on or after July 1, 2022. Sequence Disclosure: It’s relevant for applications with nucleotide and/or amino acid sequence disclosures. Sequence Listing: Modified nucleotides must be properly identified and described in the sequence listing of…

Read More

What are language-dependent free text elements in a “Sequence Listing XML”?

Language-dependent free text elements in a “Sequence Listing XML” are parts of the sequence listing that contain descriptive text which may be in a language other than English. These elements are defined in 37 CFR 1.833(b)(3). Examples might include descriptions of genetic features or experiment conditions. When these elements are initially submitted in a non-English…

Read More

How are interference searches conducted for applications with nucleotide or peptide sequences?

For patent applications containing claims directed to nucleotide or peptide sequences, the interference search process involves additional steps. According to MPEP 2304.01(a): “If the application contains a claim directed to a nucleotide or peptide sequence, the examiner must submit a request to STIC to perform an interference search of the sequence.” STIC refers to the…

Read More

Which Numeric Identifiers should appear at the beginning of a “Sequence Listing”?

According to the MPEP 2424.02, specific Numeric Identifiers must be placed at the beginning of a “Sequence Listing”. The manual states: “Numeric identifiers <110> through <170> must be set forth at the beginning of the “Sequence Listing”.“ These identifiers typically include general information about the patent application, such as the applicant name, title of the…

Read More

What are examples of indirectly self-replicating biological materials?

Indirectly self-replicating biological materials are those that require the presence of another self-replicating biological material to reproduce. The MPEP 2403.01 provides several examples: Viruses Phages Plasmids Symbionts Replication defective cells The MPEP states: “Examples of indirect replicating biological materials include viruses, phages, plasmids, symbionts, and replication defective cells.” It’s important to note that these lists…

Read More